Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.59 |
| ▸ | PIM1 | P11309 | 1/20 | 0.59 |
| ▸ | GSK3B | P49841 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 9/20 | 0.54 |
| ▸ | MEN1 | O00255 | 6/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.54 |
| ▸ | RAB9A | P51151 | 6/20 | 0.54 |
| ▸ | TP53 | P04637 | 4/20 | 0.50 |
| ▸ | MLLT1 | Q03111 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MLLT3 | P42568 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6802996 | 0.84 | TP53 (0.68) | ROCK2PIM1GSK3BNPC1MEN1 | |
| SCHEMBL24376430 | 0.83 | MLLT1 (0.71) | ROCK2PIM1GSK3BNPC1MEN1 | |
| SCHEMBL19245571 | 0.81 | ROCK2 (0.57) | ROCK2PIM1GSK3BNPC1MEN1 | |
| SCHEMBL3219488 | 0.80 | RAB9A (0.72) | ROCK2PIM1GSK3BNPC1MEN1 | |
| SCHEMBL10153708 | 0.80 | ALDH1A1 (0.67) | NPC1MEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL24376323 | 0.79 | MLLT1 (0.49) | ROCK2PIM1GSK3BNPC1MEN1 | |
| SCHEMBL21446984 | 0.79 | MLLT1 (0.60) | NPC1MEN1KMT2ARAB9ATP53 | |
| SCHEMBL22322454 | 0.78 | HPGD (0.55) | ROCK2PIM1GSK3BNPC1KMT2A | |
| SCHEMBL21447026 | 0.77 | MLLT1 (0.53) | ROCK2PIM1GSK3BNPC1MEN1 | |
| SCHEMBL6801568 | 0.75 | RAB9A (0.53) | ROCK2PIM1GSK3BNPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738040-B2 | Compounds, compositions, and methods for increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190308960-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308960-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | CFTR, ABCB4, SCNN1B | ROCK2 3219/4885PIM1 4623/4885GSK3B 2766/4885 |
| US-10738040-B2 | Compounds, compositions, and methods for increasing CFTR activity | CFTR, ABCB4, SCNN1B | ROCK2 3219/4885PIM1 4623/4885GSK3B 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.